The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Nationally, employers could see total health insurance costs rise 5.8% on average in 2025. KC won't be spared costlier ...

The lives of Americans could be dramatically improved, and in thousands of cases even saved, by increasing access to ...

New study questions benefits of GLP-1 drugs for weight loss, finding high costs with little long-term health benefit. Read ...

For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Quebec's health insurance board currently doesn't cover Ozempic and similar weight-loss medication unless they are prescribed for patients who are diagnosed with diabetes.

The government will not be paying the pharmaceutical firm Lilly £280 million to run a widely reported five-year trial into ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. | LAS VEGAS—Demand for GLP-1s has not ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...